



# Hindustan Unilever Limited

Hindustan Unilever Limited  
Unilever House, B. D. Sawant Marg  
Chakala, Andheri East  
Mumbai – 400 099  
Tel: +91 (22) 39830000  
Web: [www.hul.co.in](http://www.hul.co.in)  
CIN: L15140MH1933PLC002030

January 25, 2019

<b>National Stock Exchange of India Limited</b> Manager - Listing Compliance Department, Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051  NSE Scrip Code: HINDUNILVR	<b>BSE Limited</b> Deputy General Manager – Corporate Relationship Department, 1 <sup>st</sup> Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001.  BSE Scrip Code: 500696
--	--

Dear Sir,

**Subject : Approval of the Competition Commission of India to the proposed Amalgamation of GlaxoSmithKline Consumer Healthcare Limited with Hindustan Unilever Limited. Disclosure under Regulation 30(7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is in continuation of our earlier intimation dated December 03, 2018, wherein it was informed that the Board of Directors of Hindustan Unilever Limited (the "**Company**") had approved the Scheme of Amalgamation ("**Scheme**") of GlaxoSmithKline Consumer Healthcare Limited ("**GSKCH**") with the Company, subject to receipt of applicable regulatory approvals.

In this regard, we would like to inform you that the Competition Commission of India has, *vide* its letter dated January 23, 2019, accorded its approval for the amalgamation of GSKCH with the HUL. The copy of the order is awaited.

The Scheme remains subject to the receipt of other statutory and regulatory approvals, including the approvals of the Stock Exchanges, SEBI, the National Company Law Tribunal, and the respective shareholders and creditors of GSKCH and the Company.

You are requested to kindly take the above on record.

Yours faithfully,  
For Hindustan Unilever Limited

**Dev Bajpai**  
Executive Director, Legal and Corporate Affairs  
and Company Secretary